Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

UnitedHealth Raises 2016 Forecast, Trumps 3Q Expectations

By Tom Murphy AP Health Writer | October 18, 2016

Ken Wolter / Shutterstock.com

UnitedHealth Group hiked its 2016 earnings forecast again after its profit swelled 23 percent to nearly $2 billion in the third quarter, helped by gains both in and outside its core insurance business.

The nation’s biggest health insurer now expects adjusted, full-year earnings of about $8 per share, up from its previous forecast of $7.80 to $7.95 per share.

Wall Street had been projecting per-share earnings of $7.93, according to FactSet, and the company’s stock rose before the opening bell Tuesday.

Operating earnings jumped more than 10 percent to $2.1 billion for the company’s UnitedHealthcare business, which sells insurance and runs Medicaid plans.

The insurer added nearly a million customers through its employer-sponsored and individual coverage. Medicare Advantage membership grew 12 percent, and total enrollment topped 48 million in the quarter.

Health insurance is UnitedHealth’s main business, but it also has been growing its Optum business, which provides pharmacy benefits management and technology services and runs clinics and doctor’s offices. Operating earnings from that segment surged 36 percent to $1.5 billion after jumping 46 percent in the second quarter.

Overall, UnitedHealth earned $1.97 billion in the three-month period that ended Sept. 30, up from $1.6 billion in the previous year’s quarter. Adjusted earnings totaled $2.17 per share in the most recent quarter.

The results topped expectations on Wall Street, where analysts forecast earnings of $2.08 per share, according to Zacks Investment Research.

Total revenue grew nearly 12 percent to $46.29 billion in the quarter.

The insurer offered no update Tuesday on its performance in the Affordable Care Act’s public exchanges.

UnitedHealth said in July that it expected to lose around $850 million from its ACA-compliant individual business, which is a small slice of its total operation. CEO Stephen Hemsley told analysts that his company would have no meaningful exposure next year to the exchanges, a key element in the law’s push to expand coverage.

UnitedHealth expanded to sell coverage in 34 states this year. But next year, it will only offer insurance on exchanges in Nevada, Virginia and New York.

Other insurers also have struggled to develop that business, and defections from the exchanges are expected to hurt customer choice in many markets later this fall, when the enrollment period begins for 2017 plans.

Shares of UnitedHealth Group Inc., based in Minnetonka, Minnesota, advanced 2 percent, or $2.62 to $136.75 in premarket trading.

The insurer’s shares have climbed 14 percent since the beginning of the year. That tops both the Dow Jones Industrial Average, of which UnitedHealth is a component. It also has outpaced the performance of other major insurers like Aetna Inc. and the Blue Cross-Blue Shield carrier Anthem Inc., which are both fighting federal regulators to close multi-billion dollar acquisitions.


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE